Short-course antiretroviral therapy in primary HIV infection.

Short-course antiretroviral therapy in primary HIV infection.

BACKGROUND: Short-course antiretroviral therapy (ART) in primary human immunodeficiency virus (HIV) infection may delay disease progression but has not been adequately evaluated. METHODS: We randomly assigned adults with primary HIV infection to ART for 48 weeks, ART for 12 weeks, or no ART (standar...

Full description

Bibliographic Details
Main Authors:	Fidler, S, Porter, K, Ewings, F, Frater, J, Ramjee, G, Cooper, D, Rees, H, Fisher, M, Schechter, M, Kaleebu, P, Tambussi, G, Kinloch, S, Miro, J, Kelleher, A, McClure, M, Kaye, S, Gabriel, M, Phillips, R, Weber, J, Babiker, A
Format:	Journal article
Language:	English
Published:	Massachusetts Medical Society 2013

Similar Items

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy
by: Stöhr, W, et al.
Published: (2013)

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.
by: Wolfgang Stöhr, et al.
Published: (2013-01-01)

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection
by: Hamlyn, E, et al.
Published: (2012)

HIV-1 DNA predicts disease progression and post-treatment virological control.
by: Williams, J, et al.
Published: (2014)

Virological remission after antiretroviral therapy interruption in female African HIV seroconverters
by: Gossez, M, et al.
Published: (2018)

Protective HLA class I alleles are associated with reduced immune activation and fibrinolysis in individuals with primary HIV infection
by: Hamlyn, E, et al.
Published: (2010)

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.
by: Elizabeth Hamlyn, et al.
Published: (2012-01-01)

Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
by: Hurst, J, et al.
Published: (2015)

Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection.
by: Hamlyn, E, et al.
Published: (2012)

HIV-1 Specific CD4 Responses in Primary HIV-1 Infection predict disease progression in the SPARTAC Trial
by: Frater, A, et al.
Published: (2013)

Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy.
by: Frater, A, et al.
Published: (2002)

Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients.
by: Frater, A, et al.
Published: (2001)

HIV-1 DNA predicts disease progression and post-treatment virological control
by: James P Williams, et al.
Published: (2014-09-01)

Early antiretroviral therapy reduces hiv dna following perinatal HIV infection
by: Foster, C, et al.
Published: (2017)

Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcome.
by: Frater, J, et al.
Published: (2002)

Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants.
by: English, S, et al.
Published: (2011)

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection.
by: Fidler, S, et al.
Published: (2002)

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection.
by: Fidler, S, et al.
Published: (2002)

HIV-1 resistance genotyping by sequencing produces inconsistent results for mixed viral populations.
by: Frater, A, et al.
Published: (2000)

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial
by: Fidler, S, et al.
Published: (2020)

HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection.
by: Duda, A, et al.
Published: (2009)

Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound
by: P. Zacharopoulou, et al.
Published: (2022-01-01)

Simple detection of point mutations associated with HIV-1 drug resistance.
by: Frater, A, et al.
Published: (2001)

TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals.
by: Angus, B, et al.
Published: (2008)

A randomised controlled trial comparing the impact of Antiretroviral Therapy (ART) with a ‘Kick-and-Kill’ approach to ART alone on HIV reservoirs in individuals with primary HIV infection (PHI); RIVER trial
by: Fidler, S, et al.
Published: (2018)

Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection
by: Hoffmann, M, et al.
Published: (2016)

4 Post-treatment control or treated controllers? The impact of ART on time to viral rebound in recent seroconverters
by: G.E. Martin, et al.
Published: (2016-07-01)

P07-09. Contemporaneous transmission of genetically distinct HIV variants from a single donor to two recipients
by: English, S, et al.
Published: (2009)

P07-09. Contemporaneous transmission of genetically distinct HIV variants from a single donor to two recipients
by: McClure M, et al.
Published: (2009-10-01)

CD32-expressing CD4 T cells are phenotypically diverse and can contain proviral HIV DNA
by: Martin, G, et al.
Published: (2018)

HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper
by: S. Fidler, et al.
Published: (2021-03-01)

Contemporaneous transmission of genetically distinct HIV variants from a single donor to two recipients
by: English, S, et al.
Published: (2009)

Baseline polymorphisms found in patients infected with non-clade BHIV-1 do not affect outcome to HAART
by: Frater, A, et al.
Published: (2000)

Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections
by: Barnes, E, et al.
Published: (2010)

HIV-1 drug resistance in primary infections in the UK.
by: Fidler, S, et al.
Published: (2001)

Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort.
by: Fidler, S, et al.
Published: (2007)

B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection
by: Huang, K, et al.
Published: (2010)

The role of the gut mucosa in protection from HIV-1 in highly exposed persistently seronegative individuals (HEPS)
by: Fox, J, et al.
Published: (2009)

Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors.
by: Russell, R, et al.
Published: (2005)

How soon after HIV seroconversion is antiretroviral therapy initiated?
by: Babiker, A, et al.
Published: (1999)